IMBdx Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
60
- Stock Symbol
-
461030
- Share Price
-
$1.65
- (As of Friday Closing)
IMBdx General Information
Description
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.
Contact Information
Website
www.imbdx.comCorporate Office
- 131 Gasan Digital 1-ro, Geumcheon-gu
- 21st Floor, Building A, BYC High City Building
- Seoul, 08506
- South Korea
Corporate Office
- 131 Gasan Digital 1-ro, Geumcheon-gu
- 21st Floor, Building A, BYC High City Building
- Seoul, 08506
- South Korea
IMBdx Stock Performance
As of 20-Nov-2026, IMBdx’s stock price is $1.65. Its current market cap is $23.7M with 14.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.65 | $1.60 | $1.32 - $8.78 | $23.7M | 14.3M | 16.8K | -$0.37 |
IMBdx Financials Summary
As of 30-Jun-2026, IMBdx has a trailing 12-month revenue of $3.86M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 20,967 | 80,531 | 81,131 | |
| Revenue | 3,858 | 3,744 | 2,497 | 3,080 |
| EBITDA | (4,609) | (5,007) | (6,439) | (6,149) |
| Net Income | (5,229) | (5,575) | (7,019) | (7,967) |
| Total Assets | 15,973 | 18,833 | 23,115 | 7,621 |
| Total Debt | 205 | 304 | 294 | 249 |
IMBdx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IMBdx Comparisons
Industry
Financing
Details
IMBdx Competitors (6)
One of IMBdx’s 6 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GRAIL | Formerly VC-backed | Menlo Park, CA | ||||
| GC Genome | Corporation | Yongin-si, South Korea | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Freenome | Formerly VC-backed | Brisbane, CA | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA |
IMBdx Patents
IMBdx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026197667-A1 | Early cancer screening method using methylation signal and information provision device using same | Pending | 18-Mar-2025 | ||
| EP-4282984-A1 | Method for construction of multi-feature prediction model for cancer diagnosis | Pending | 29-Mar-2022 | ||
| EP-4282984-A4 | Method for construction of multi-feature prediction model for cancer diagnosis | Pending | 29-Mar-2022 | ||
| WO-2023191197-A1 | Method for construction of multi-feature prediction model for cancer diagnosis | Inactive | 29-Mar-2022 | ||
| EP-4287213-A1 | Method for predicting cancer recurrence using patient-specific panel | Pending | 29-Mar-2022 | C12Q1/6886 |
IMBdx Signals
IMBdx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IMBdx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
IMBdx FAQs
-
When was IMBdx founded?
IMBdx was founded in 2018.
-
Where is IMBdx headquartered?
IMBdx is headquartered in Seoul, South Korea.
-
What is the size of IMBdx?
IMBdx has 60 total employees.
-
What industry is IMBdx in?
IMBdx’s primary industry is Drug Discovery.
-
Is IMBdx a private or public company?
IMBdx is a Public company.
-
What is IMBdx’s stock symbol?
The ticker symbol for IMBdx is 461030.
-
What is the current stock price of IMBdx?
As of 20-Nov-2026 the stock price of IMBdx is $1.65.
-
What is the current market cap of IMBdx?
The current market capitalization of IMBdx is $23.7M.
-
What is IMBdx’s current revenue?
The trailing twelve month revenue for IMBdx is $3.86M.
-
Who are IMBdx’s competitors?
GRAIL, GC Genome, Foundation Medicine, Freenome, and Guardant Health are some of the 6 competitors of IMBdx.
-
What is IMBdx’s annual earnings per share (EPS)?
IMBdx’s EPS for 12 months was -$0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process